Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Summary
- There are no head-to-head comparisons between either raltegravir or dolutegravir and elvitegravir in first-line therapy
- The phase III SPRING-2 trial compared raltegravir with dolutegravir, each with investigator-selected abacavir/lamivudine or emtricitabine/tenofovir DF
- At Week 48, once-daily dolutegravir was noninferior to twice-daily raltegravir with 88% vs 85% of patients, respectively, with HIV-1 RNA < 50 copies/mL based on US FDA snapshot analysis[Raffi 2013a]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content